Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
On 26 January 2026 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2026〕2号, "Several Measures of Beijing Dongcheng District on Promoting High-Quality Development of the Pharmaceutical and Health Industry," effective 25 February 2026. The 14-article package spans seven chapters covering traditional-Chinese-medicine industry development, product-innovation value realisation, digital medical services, innovative-medicine support, and talent services, with cash grants of up to RMB 20 million per project and up to RMB 10 million per year for a single market entity in the medical-device segment. A draft version was open for public comment from 18 December 2025 to 17 January 2026 before formal issuance.
China's Ministry of Finance, NDRC, Ministry of Industry and Information Technology, People's Bank of China and National Financial Regulatory Administration jointly issued Cai Jin [2026] No. 4 on 2026-01-19, establishing a central-fiscal loan interest-subsidy scheme for micro, small and medium-sized enterprises (MSMEs) operating in 14 designated industrial-chain and emerging-industry sectors. Eligible loans originated from 2026-01-01 receive a 1.5-percentage-point annual interest subsidy for up to two years, capped at RMB 50 million in principal per enterprise (maximum subsidy RMB 1.5 million per enterprise). The policy is tentatively set to run one year with a possible extension.
On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 2, "Several Measures on Focusing on Translational Medicine to Accelerate Industry-Medicine Integration Innovation and Development," effective 30 days after promulgation (4 February 2026 per Global Trade Alert tracking) and valid through 31 December 2027. The measures subsidize cell-and-gene therapy, mRNA, synthetic biology, regenerative medicine and digital-medicine R&D (up to CNY 2m/year per entity), platform/lab construction (up to 30% of investment, capped at CNY 2m), use of the district's translational-medicine national science facility (up to 50% of annual usage fee, capped at CNY 1m), and domestic Class 1 new-drug clinical trials (Phase I up to CNY 2m, Phase II up to CNY 5m, capped at CNY 50m/year per entity), plus annual support for biopharma industrial- park operators (up to CNY 2m/year).
On 12 November 2025 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2025〕12号, "Several Measures of Beijing Dongcheng District on Promoting Science and Technology Innovation Development," effective 12 December 2025 through 31 December 2028. The package tiers cash grants by milestone: up to RMB 100,000 for first-time high-tech-enterprise certification, RMB 1 million for first-to-market new technology/products, RMB 10 million for incubator and specialised industrial-park upgrades, and up to RMB 30 million for "chain-leader" enterprises or innovation-driving market entities judged to have significant regional radiating/spillover effect. Eligible sectors span new-generation information technology, cultural technology, pharmaceuticals and health, intelligent manufacturing, new materials, and green energy/environmental protection.
On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.